Literature DB >> 33297722

Astrocyte Glutamate Uptake and Water Homeostasis Are Dysregulated in the Hippocampus of Multiple Sclerosis Patients With Seizures.

Andrew S Lapato1,2, Sarah M Thompson1, Karen Parra1, Seema K Tiwari-Woodruff1,2,3.   

Abstract

While seizure disorders are more prevalent among multiple sclerosis (MS) patients than the population overall and prognosticate earlier death & disability, their etiology remains unclear. Translational data indicate perturbed expression of astrocytic molecules contributing to homeostatic neuronal excitability, including water channels (AQP4) and synaptic glutamate transporters (EAAT2), in a mouse model of MS with seizures (MS+S). However, astrocytes in MS+S have not been examined. To assess the translational relevance of astrocyte dysfunction observed in a mouse model of MS+S, demyelinated lesion burden, astrogliosis, and astrocytic biomarkers (AQP4/EAAT2/ connexin-CX43) were evaluated by immunohistochemistry in postmortem hippocampi from MS & MS+S donors. Lesion burden was comparable in MS & MS+S cohorts, but astrogliosis was elevated in MS+S CA1 with a concomitant decrease in EAAT2 signal intensity. AQP4 signal declined in MS+S CA1 & CA3 with a loss of perivascular AQP4 in CA1. CX43 expression was increased in CA3. Together, these data suggest that hippocampal astrocytes from MS+S patients display regional differences in expression of molecules associated with glutamate buffering and water homeostasis that could exacerbate neuronal hyperexcitability. Importantly, mislocalization of CA1 perivascular AQP4 seen in MS+S is analogous to epileptic hippocampi without a history of MS, suggesting convergent pathophysiology. Furthermore, as neuropathology was concentrated in MS+S CA1, future study is warranted to determine the pathophysiology driving regional differences in glial function in the context of seizures during demyelinating disease.

Entities:  

Keywords:  demyelination; epilepsy; neuropathology

Year:  2020        PMID: 33297722      PMCID: PMC7734542          DOI: 10.1177/1759091420979604

Source DB:  PubMed          Journal:  ASN Neuro        ISSN: 1759-0914            Impact factor:   4.146


Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that affects roughly 913,925 in the United States (Wallin et al., 2019). Neurological symptomology in MS is multifarious, owing to the largely non-stereotyped distribution of leukocytic lesions throughout the brain and spinal cord of MS patients. In addition to the loss of myelin at the site of autoimmune attack, denuded axons within the lesion undergo various deleterious changes (Trapp et al., 1998; Nave & Trapp, 2008), producing deficits in autonomic, cognitive, motor, sensory, and visual function (Rosenthal et al., 2020). While these outcomes are well-characterized, epileptic seizures are observed at a rate three times higher in MS patients than the population overall for reasons that are incompletely understood (Poser & Brinar, 2003; Catenoix et al., 2011). Both partial and generalized seizures are commonly identified in MS patients with seizure disorders (MS+S), although primary and secondary generalized subtypes account for approximately 67% of cases (Moreau et al., 1998; Nyquist et al., 2001; Spatt et al., 2001; Koch et al., 2008; Shaygannejad et al., 2013). Unusual seizure manifestations are also reported by these patients, including dysphasic/aphasic status epilepticus and musicogenic seizures (Newman & Saunders, 1980; Spatt et al., 1994; Primavera et al., 1996). Seizures may herald or occur contemporaneous to relapse in a subset of MS+S patients (Kelley & Rodriguez, 2009; Catenoix et al., 2011; Shaygannejad et al., 2013; Lund et al., 2014; Uribe-San-Martin et al., 2014) and rise in incidence with disease duration (Striano et al., 2003; Martínez-Juárez et al., 2009; Lund et al., 2014; Colasanti et al., 2016). Although their etiology remains unclear, seizures in MS are associated with poor response to traditional anti-epileptic drugs (AEDs), which may precipitate relapse-like symptoms, worsen neurological dysfunction, or engender seizures (Moreau et al., 1998; Solaro et al., 2005; Catenoix et al., 2011; Colasanti et al., 2016; Burman & Zelano, 2017). While seizures in MS produce significantly worse health outcomes and are poorly controlled by AEDs, their pathophysiology and risk factors are poorly understood. Though limited in number, paraclinical studies examining MS+S have yielded some insight into distinguishing features of seizures arising during MS. MS patients with seizures exhibit a variety of electroencephalographic (EEG) abnormalities that localize to structures associated with seizure in temporal lobe epilepsy, suggesting commonality between the two disorders. In addition to a varying degree of diffuse slowing across monitored sites, EEG recordings from MS+S patients display sharp- and slow-wave complexes, high amplitude delta waves, and rhythmic interictal discharges in frontotemporal areas (Ghezzi et al., 1990; Moreau et al., 1998; Striano et al., 2003; Martinez-Lapiscina et al., 2013). In addition to possessing possible diagnostic value, these studies confirm that seizures in MS patients are electrographically identifiable and may follow a similar course of disease. Magnetic resonance imaging (MRI) studies examining cortical structures showing EEG irregularities in MS+S patients have identified differences in lesion phenotype and distribution relative to MS patients without seizures. Along with abundant grey matter lesions (GMLs), large cortical lesions that extend across adjacent gyri are observed in MS+S more frequently that other MS patients (Calabrese et al., 2008, 2012). Subcortical areas are similarly affected in MS+S: limbic structures implicated as seizure foci in patients with temporal lobe epilepsy display significant damage, including accumulation of enhancing lesions in the hippocampal formation, cingulate cortex, and insula (Calabrese et al., 2017). In addition to showing temporal lobe atrophy that outpaces other cortical areas, MS+S hippocampi harbor nearly four times as many GMLs than MS only, with similarly high ratios observed in abutting structures (Calabrese et al., 2017). While these studies support a role for enhanced inflammatory lesion burden in MS patients with seizures, their ability to clarify the cellular mechanism driving seizures in MS is limited. Thus, direct observation of possible cellular and molecular players in the etiology of MS+S is warranted. Immunohistochemical examination of postmortem MS+S brain tissue supports may provide some insight into the mechanism driving seizures in MS. In a cohort of postmortem specimens from the United Kingdom MS Tissue Bank, Nicholas et al. observed that the number of GABAergic neurons, identified by immunoreactivity for the GABA synthetic enzyme glutamate decarboxylase (GAD)67, was reduced in layers IV & VI of the middle temporal gyrus of MS+S donors relative to MS only donors (Nicholas et al., 2016). Interestingly, this study also showed that loss of GABAergic populations is independent of local leukocytic infiltration or compromised cellular respiration, leaving the etiology of GABAergic cell loss in MS+S uncertain (Nicholas et al., 2016). These findings are analogous to temporal lobe epilepsy (TLE) and are thought to facilitate the initiation and spread of seizures (de Lanerolle et al., 2012; Huusko et al., 2015), suggesting that MS+S involves similar disinhibition of neocortical circuits. Translational studies point to a second possible avenue by which neuronal excitability may be dysregulated in MS+S. Concomitant to loss of GABAergic neurons, mice with demyelination-induced seizures display marked hippocampal astrogliosis with perturbed expression of the astrocyte water channel aquaporin(AQP)4 (Lapato et al., 2017). Although the specific contribution of AQP4 to seizures is complex and not fully delineated, these observations mirror a growing body of literature implicating astrocytes in the pathophysiology of epilepsy. Astrocyte processes critical to the maintenance of normal neuronal excitation are disordered in epilepsy, including impaired regulation of synaptic glutamate, disruption of water homeostasis, and delayed clearance of extracellular K+ (Bergles & Jahr, 1998; Eid et al., 2005; Takahashi et al., 2010; Lee et al., 2012a; Alvestad et al., 2013; Coulter & Steinhauser, 2015). Several of these are critically mediated by gap junction coupling among astrocytes linked into a glial syncytium, leading at least one group to indict astrocyte uncoupling in the etiology of epileptic seizures (Tress et al., 2012; Bedner & Steinhauser, 2013; Chever et al., 2014b; Bedner et al., 2015; Lapato & Tiwari-Woodruff, 2018). Yet as TLE pathophysiology involves myriad cellular and molecular actors, the degree to which TLE & MS+S neuropathology converges has not been established. Here, we examine astrocyte dysfunction in a cohort of postmortem hippocampal tissue from MS patients with and without seizures obtained from the NIH NeuroBioBank/Human Brain & Spinal Fluid Resource Center (HBSFRC) brain bank at the University of California Los Angeles (UCLA). Specifically, we examined expression of astrocyte-derived molecules involved in homeostatic neuronal excitability that are impacted in epilepsy as well as demyelination extent. These targets include the water channel AQP4, the relevance of which is noted above, the primary synaptic glutamate transporter in the adult mammalian CNS, excitatory amino acid transporter (EAAT)2 (Holmseth et al., 2009; Rimmele & Rosenberg, 2016), and the primary astrocyte-expressed gap junction component protein, connexin (CX)43. Our data suggest that, while demyelination was comparable in the HBSFRC cohort, astrocytes displayed marked changes in the MS+S group, including reduced clearance of synaptic glutamate, impaired water & potassium (K+)buffering, and altered gap junction coupling between astrocytes. As new, more efficacious interventions are necessary for the management of MS+S, this study lays the groundwork for further translational study probing the contribution of astrocytes to demyelination-induced seizures.

Materials and Methods

Human Postmortem Hippocampal Specimens

Human tissue was acquired from the NIH NeuroBioBank/HBSFRC at UCLA with a history of MS and MS preceding seizure disorder diagnosis. Tissues arrived with limited cause of death and neuropathology reports with all identifying patient data removed. EDSS scores or frequency of seizures was not disclosed in specimen information provided. Donor age at death, autolysis time, and cohort gender composition and more detailed information is presented in Table 1 and Supplemental Table. Due to anatomical variability in HBSFRC samples, not all sections contained all hippocampal subregions analyzed, leading to n values below cohort totals.
Table 1.

Summary of Patient Demographics of Specimens Acquired From HBSFRC.

DiseasenMS phenotypeAge at death (yrs±SD)Autolysis time (hrs±SD)
MS only21 (12 ♀, 9 ♂)MS, RRMS, SPMS65.6 ± 9.316.4 ± 7.5
MS+S7 (4 ♀, 3 ♂)MS, SPMS61.9 ± 13.320.3 ± 10.1

SD = standard deviation, MS = multiple sclerosis, RRMS = relapsing-remitting MS, SPMS = secondary progressive MS.

Summary of Patient Demographics of Specimens Acquired From HBSFRC. SD = standard deviation, MS = multiple sclerosis, RRMS = relapsing-remitting MS, SPMS = secondary progressive MS.

Immunohistochemistry

Tissues were received from HBSFRC frozen, whereupon they were gradually thawed at 4 °C followed by two hours fixation in 10% neutral buffered formalin (Fisher Scientific, Hampton, NH) at the same temperature. Following incubation, specimens were cryoprotected in 30% w/v sucrose in phosphate buffered saline (PBS) with 0.2% w/v NaN3 (both Millipore Sigma, St. Louis, MO) and incubated at 4 °C until tissue density exceeded that of the sucrose solution. Once cryoprotection was complete, specimens were embedded in Tissue-Tek Cryo-OCT compound (Andwin Scientific, Los Angeles, CA) and 40 μm sections were cut using an HM525 cryostat (Thermo Fisher Scientific, Waltham, MA) and stored in PBS with 0.1% w/v NaN3 4 °C until use. 40 μm free floating postmortem hippocampal specimens were immunostained following a previously described procedure (Hasselmann et al., 2017; Mangiardi et al., 2011). All antibodies & dilutions used in the present study are denoted in Table 2 (obtained from Millipore Sigma & Invitrogen, Carlsbad, CA). Primary antibodies were diluted in PBS and detection antibodies were diluted in tris-buffered saline (TBS). For chromogen myelin labeling, after incubation with horseradish peroxidase (HRP)-conjugated detection antibody, MOG immunoreactivity was visualized using the 3,3’-diaminobenzidine (DAB) Peroxidase (HRP) Substrate Kit (Vector Laboratories, Burlingame, CA), mounted to slides, counterstained with Hematoxylin QS (Vector Laboratories), then cover-slipped using Permount non-aqueous medium (Fisher Scientific). For fluorescent microscopy, after incubation with fluorophore-conjugated antibodies, sections were counterstained in TBS containing 4’,6-diamidino-2-phenylindole (DAPI, 2 ng/ml; Molecular Probes), mounted on glass slides, and cover-slipped in Fluoromount G aqueous medium (Thermo Fisher Scientific).
Table 2.

Primary and Detection Antibodies Utilized With Manufacturer Information and Concentration Used.

AntibodyManufacturerCatalogue #RRIDDilution
mouse anti-myelin oligodendrocyte glycoprotein (MOG)Millipore SigmaMAB5680AB_15872781:500
chicken anti-glial fibrillary acidic protein (GFAP)Millipore SigmaAB5541AB_1775211:1000
rabbit anti-aquaporin-4 (AQP4)Millipore SigmaAB2218AB_11633831:500
guinea pig anti-glutamate transporter, glial (EAAT2)Millipore SigmaAB1783AB_909491:1000
rabbit anti-connexin 43 (CX43)Millipore SigmaC6219AB_4768571:500
goat anti-mouse IgG (H + L), horseradish peroxidaseMillipore SigmaAP308PAB_112157961:500
goat anti-chicken Ig (H + L), DyLight 650InvitrogenSA5-10073AB_255665310 μg/mL
goat anti-rabbit IgG (H + L), Alexa Fluor +555InvitrogenA32732AB_26332811:500
goat anti-rabbit IgG (H + L), Alexa Fluor +488InvitrogenA32731AB_26332801:500
goat anti-rabbit IgG (H + L), Cy3Millipore SigmaAP108CAB_924221:500
Primary and Detection Antibodies Utilized With Manufacturer Information and Concentration Used.

Imaging and Quantification

Chromogen-stained hippocampi were imaged using a Leica DM5500 B upright transmitted light microscope (Leica Microsystems Inc., Buffalo Grove, IL) at 5X magnification, then stitched into segments using a pairwise-stitching algorithm (Preibisch et al., 2009) included with the Fiji ImageJ package (Schindelin et al., 2012), and segments were assembled in Adobe Illustrator (Adobe Inc., San Jose, CA). Fluorescence micrographs were acquired on an Olympus BX61 confocal microscope (Olympus America Inc., Center Valley, PA) at 20X magnification. ≤20 μm thick z-stack projections were compiled using SlideBook 6 software (Intelligent Imaging Innovations, Inc., Denver, CO) or Olympus cellSens software (Olympus America Inc.). Image analysis was carried out in Fiji software. Data points represent average values for two fields of view per area per donor sample. Fields were selected away from active lesions and large white matter tracts to assess normal appearing gray matter, equating to stratum radiatum in CA1 & CA3 and hilus in DG. Lesion density was calculated by delineating rough lesion borders in stitched images then normalizing lesion counts to total area within each of the 3 subregions analyzed. Signal intensity (mean gray value) was measured in regions of interest containing CA1/CA3 stratum radiatum and pyramidal cell layer or hilus/CA4 for DG and normalized to minimum/maximum values for the entire HBSFRC cohort.

Statistical Analysis

Statistical analysis was carried out per previously published work (Tiwari-Woodruff et al., 2007; Crawford et al., 2010). All statistics were performed using Prism 8 software (GraphPad Software, La Jolla, CA). Differences were considered significant at p ≤ 0.05 and denoted by the addition of an asterisk (*) above the statistically different data sets. All statistical tests used to determine significance are noted in corresponding figure legends. N values included in each analysis are represented as individual points in scatter plots shown. Anatomical variation within HBSFRC tissues circumscribed the number of specimens available for DG analysis, leading to reduced data points within those plots.

Results

Donor Demographic Data and Characteristics of Specimens Obtained from the HBSFRC

Hippocampi from 21 MS and 7 MS+S donors were obtained from the HBSFRC (Table 1). The MS only cohort was 57.1% female and 42.9% male and was composed of donors with relapsing-remitting MS (RRMS; 23.8%), secondary progressive (SPMS; 33.3%), and non-specified MS (42.9%) disease phenotypes. Average age at death for this group was 64.6 ± 10.5 & 66.9 ± 7.9 years for female and male donors, respectively, and a cohort average of 65.6 ± 9.3. Autolysis time was comparable between male (14.7 ± 8.9 hours) and female (27.6 ± 6.3 hours) specimens, with an aggregate average of 16.4 ± 7.5 hours. Neither age at death (p = 0.5871) or autolysis time (p = 0.3807) were statistically different between male and female donors within the MS only group. The MS+S cohort was divided equally between female and male donors, with 42.9% of donors diagnosed with SPMS and 57.1% having an unspecified MS phenotype. Female donors were aged 59.8 ± 15.9 years at time of death and male donors 64.8 ± 11.6, for a cohort average of 61.9 ± 13.4 years. On average, female specimens waited 14.6 ± 3.6 hours and male specimens 27.9 ± 11.6 hours until cryopreservation (cohort average = 20.3 ± 10.1 hours). No differences were identified in age at death (p = 0.6722) or autolysis time (p = 0.0763) between male and female specimens in the MS+S cohort. No differences were observed in age at death (p = 0.4195) or autolysis time (p = 0.2829) when comparing MS and MS+S groups overall or when divided by sex (male: age at death p = 0.7112, autolysis time p = 0.0636; female: age at death p = 0.4912, autolysis time p = 0.3727).

Brain Slice Integrity and Identifications of Structures to Compare

Initially, slices from all postmortem specimens were Nissl stained to assess tissue integrity and delineate anatomical boundaries of subregions. Most, but not all, slices displayed coronally sectioned hippocampal formation with some abutting structures as depicted in Figure 1 schematic drawing. Cornu Ammonis (CA)1, CA3 and dentate gyrus (DG) were identified based on cytoarchitecture (Figure 1A to C) and mapped for subsequent analysis and comparison. These subregions were chosen as they represent most major functionally distinct gray matter structures participating in the hippocampal trisynaptic circuit (Wojtowicz, 2012) and frequently display pathological changes in epilepsy (de Lanerolle et al., 2012). DG was either only partially represented or absent in approximately 1/3rd of samples. CA1 & CA3 were analyzed in these specimens but no data was acquired for DG comparisons.
Figure 1.

Illustrated human hippocampal anatomy and cytoarchitecture characteristic of CA1, CA3, & DG images used for analysis. Diagram shows human hippocampus with subiculum (Sub), CA1, CA3, CA4, and dentate gyrus (DG) with strata oriens (SO), pyramidale (SP), radiatum (SR), and lacunosum-moleculare, as well as granule cell layer (GCL), noted. Dashed boxes correspond to representative 5X Nissl stained cytoarchitecture (shown in insets A–C) used to identify regions for confocal imaging.

Illustrated human hippocampal anatomy and cytoarchitecture characteristic of CA1, CA3, & DG images used for analysis. Diagram shows human hippocampus with subiculum (Sub), CA1, CA3, CA4, and dentate gyrus (DG) with strata oriens (SO), pyramidale (SP), radiatum (SR), and lacunosum-moleculare, as well as granule cell layer (GCL), noted. Dashed boxes correspond to representative 5X Nissl stained cytoarchitecture (shown in insets A–C) used to identify regions for confocal imaging.

MS and MS+S Hippocampi Obtained from the HBSFRC Display Similar Demyelinated Lesion Burden

Imaging studies report greater numbers of demyelinating lesions in the hippocampi of MS+S patients relative to MS patients without seizures (Calabrese et al., 2017). To establish whether the HBSFRC cohort displays similar differences in myelination, immunolabeling for myelin oligodendrocyte glycoprotein (MOG) was performed and the density of lesions in CA1, CA3, and DG were measured (Figure 2).
Figure 2.

Demyelinated lesion burden is similar in the HBSFRC cohort. A: Representative 5X stitched micrographs showing MOG immunoreactivity in MS & MS+S hippocampus visualized by HRP-DAB chromogen immunohistochemistry with hematoxylin counterstain. CA1, CA3, DG, & Sub are indicated. Demyelinated lesions are traced by red dashed line. Black dashed lines represent divisions between subregions. B–D: Quantification of lesion distribution in MS & MS+S tissues. Comparison of demyelinated lesion density in CA1 (B), CA3 (C), and DG (D) revealed no significant difference in lesion burden between MS & MS+S specimens. Unpaired t-test.

Demyelinated lesion burden is similar in the HBSFRC cohort. A: Representative 5X stitched micrographs showing MOG immunoreactivity in MS & MS+S hippocampus visualized by HRP-DAB chromogen immunohistochemistry with hematoxylin counterstain. CA1, CA3, DG, & Sub are indicated. Demyelinated lesions are traced by red dashed line. Black dashed lines represent divisions between subregions. B–D: Quantification of lesion distribution in MS & MS+S tissues. Comparison of demyelinated lesion density in CA1 (B), CA3 (C), and DG (D) revealed no significant difference in lesion burden between MS & MS+S specimens. Unpaired t-test. Demyelinated lesions were observed in both MS & MS+S groups that varied in their size and involvement of adjacent structures (Figure 2A). Quantification of lesion density in hippocampal subregions revealed no difference in lesion burden in CA1, CA3, or DG between MS & MS+S specimens in the HBSFRC cohort (Figure 2B to D).

GFAP+ Astrogliosis is More Pronounced in the CA1 Subfield of MS Patients with Seizures

Astrogliosis, identified by proliferation of astrocytes and upregulation of the intermediate filament GFAP, is a commonly observed feature of various neurological diseases, including MS and epilepsy (de Lanerolle et al., 2012; Brosnan & Raine, 2013). Reactive astrocytes undergo changes to their metabolism and physiology that exacerbate disease severity and could facillitate seizures, including attenuation of glutamate transporter activity (Vercellino et al., 2007; Azevedo et al., 2014), release of reactive O2/N2 species (Gavillet et al., 2008), and loss of gap junction coupling-mediated K+ homeostasis (Bedner et al., 2015; Karim et al., 2018). Thus, to identify differences in the extent of astrogliosis between MS & MS+S specimens, GFAP+ immunoreactivity was assessed in CA1, CA3, and DG subfields GFAP+ signal intensity was elevated in MS+S CA1 relative to MS only (Figure 3A and B). No difference in GFAP+ signal intensity was observed in CA3 or DG subfields (Figure 3C to F). No difference was observed in the total GFAP+ immunoreactive area fraction between MS & MS+S in any region (not shown), suggesting increased signal intensity was not due to differences in number of GFAP+ cells or coverage of GFAP+ processes.
Figure 3.

GFAP+ astrogliosis is more pronounced in the CA1 subfield of MS patients with seizures. A–C: Representative 20X micrographs showing astrocytes (GFAP; green) with nuclear counterstain (DAPI; red) in CA1, CA3, & DG of MS & MS+S hippocampi. Insets a and b show digitally magnified area within dashed boxes for detail. D-F) Normalized GFAP immunoreactive signal intensity in MS & MS+S CA1 (D), CA3 (E), and DG in shown in arbitrary units (A.U.). Relative to MS, GFAP+ signal intensity was greater in CA1 of MS+S specimens. No difference was observed in CA3 or DG. Unpaired t test.

GFAP+ astrogliosis is more pronounced in the CA1 subfield of MS patients with seizures. A–C: Representative 20X micrographs showing astrocytes (GFAP; green) with nuclear counterstain (DAPI; red) in CA1, CA3, & DG of MS & MS+S hippocampi. Insets a and b show digitally magnified area within dashed boxes for detail. D-F) Normalized GFAP immunoreactive signal intensity in MS & MS+S CA1 (D), CA3 (E), and DG in shown in arbitrary units (A.U.). Relative to MS, GFAP+ signal intensity was greater in CA1 of MS+S specimens. No difference was observed in CA3 or DG. Unpaired t test.

Reduced AQP4 Expression in MS+S CA1 and CA3 Subregions with Loss of Vascular Localization

The glial water channel AQP4 is thought to play a role in maintenance of extracellular space volume and facilitation of ion movement throughout cytoplasmically linked glial networks (Binder et al., 2006; Strohschein et al., 2011). Perturbation of AQP4 expression and localization away from its normal perivascular distribution is commonly observed in hippocampi of epileptic patients (Lee et al., 2004; Eid et al., 2005) as well as in experimental models (Lee et al., 2012b; Alvestad et al., 2013; Hubbard et al., 2016). To assess whether MS+S involves similar changes to AQP4, its expression was evaluated in MS & MS+S hippocampi. Relative to MS only, MS+S CA1 and CA3 exhibited reduced AQP4 staining intensity (Figure 4A and B, D and E). No statistically significant difference was observed in MS+S DG (Figure 4C and F), although AQP4 immunoreactive area fraction trended toward increase in MS+S DG (not shown, p = 0.0605). Of interest, while AQP4 signal was enriched proximal to putative blood vessels in MS CA1, perivascular AQP4 staining was infrequent in MS+S CA1 (Figure 4A, arrowheads). No differences were noted in perivascular AQP4 in CA3 and DG.
Figure 4.

AQP4 expression is decreased in MS+S CA1 & CA3 subregions with loss of perivascular localization in the HBSFRC cohort. A–C: Representative 20X micrographs showing AQP4 (red) with nuclear counterstain (DAPI; blue) in CA1, CA3, & DG of MS & MS+S hippocampi. Insets a and b show digitally magnified area within dashed boxes for detail. Note reduced perivascular AQP4 localization in MS+S CA1 (arrowheads). D–F: Normalized GFAP immunoreactive signal intensity in MS & MS+S CA1 (D), CA3 (E), and DG in shown in arbitrary units (A.U.). Relative to MS, AQP4 expression was reduced in MS+S CA1 & CA3. No difference was observed in DG. Unpaired t test.

AQP4 expression is decreased in MS+S CA1 & CA3 subregions with loss of perivascular localization in the HBSFRC cohort. A–C: Representative 20X micrographs showing AQP4 (red) with nuclear counterstain (DAPI; blue) in CA1, CA3, & DG of MS & MS+S hippocampi. Insets a and b show digitally magnified area within dashed boxes for detail. Note reduced perivascular AQP4 localization in MS+S CA1 (arrowheads). D–F: Normalized GFAP immunoreactive signal intensity in MS & MS+S CA1 (D), CA3 (E), and DG in shown in arbitrary units (A.U.). Relative to MS, AQP4 expression was reduced in MS+S CA1 & CA3. No difference was observed in DG. Unpaired t test.

Synaptic Glutamate Clearance Is Likely Impaired in the CA1 of MS+S Specimens Obtained From HBSFRC

The glial glutamate/aspartate transporter EAAT2 is the most widely distributed glutamate transporter in the adult mammalian brain (Lehre & Danbolt, 1998). As regional loss of glutamate transporters and accumulation of extracellular glutamate is observed in both MS and temporal lobe epilepsy (Mathern et al., 1999; Werner et al., 2001; Proper et al., 2002; Vercellino et al., 2007; Azevedo et al., 2014), differences in EAAT2 immunostaining were assessed in MS & MS+S hippocampi. EAAT2 staining intensity was diminished in MS+S CA1 relative to MS only (Figure 5A and D). In contrast, no statistically significant difference was observed in EAAT2 signal strength in CA3 (Figure 5B and E) or DG (Figure 5C and F). However, while EAAT2 immunoreactive area fraction was not statistically different in CA1 or CA3 subregions, EAAT2+ area fraction was decreased in DG, suggesting reduced coverage of glutamate transporters in this area (not shown, p = 0.0241).
Figure 5.

EAAT2 expression is reduced in the CA1 of MS+S specimens obtained from the HBSFRC. A–C: Representative 20X micrographs showing EAAT2 (gray) with nuclear counterstain (DAPI; red) in CA1, CA3, & DG of MS & MS+S hippocampi. Insets a and b show digitally magnified area within dashed boxes for detail. D–F: Normalized EAAT2 immunoreactive signal intensity in MS & MS+S CA1 (D), CA3 (E), and DG in shown in arbitrary units (A.U.). Relative to MS, EAAT2+ signal intensity was greater in CA1 of MS+S specimens. No difference was observed in CA3 or DG. Unpaired t test.

EAAT2 expression is reduced in the CA1 of MS+S specimens obtained from the HBSFRC. A–C: Representative 20X micrographs showing EAAT2 (gray) with nuclear counterstain (DAPI; red) in CA1, CA3, & DG of MS & MS+S hippocampi. Insets a and b show digitally magnified area within dashed boxes for detail. D–F: Normalized EAAT2 immunoreactive signal intensity in MS & MS+S CA1 (D), CA3 (E), and DG in shown in arbitrary units (A.U.). Relative to MS, EAAT2+ signal intensity was greater in CA1 of MS+S specimens. No difference was observed in CA3 or DG. Unpaired t test.

CX43 Expression Is Increased in MS+S CA3

Connexins represent a group of transmembrane proteins that assemble into large, pore forming complexes permeable to a variety of cytoplasmic contents up to 1.5 kDa (Loewenstein, 1981), including ions, metabolites, and purinergic signaling molecules (Loewenstein, 1981). Disruption of gap junction coupling or aberrant hemichannel signaling may be involved in the pathogenesis of neurological disease with seizure or excitotoxic manifestations such as epilepsy (Bedner et al., 2015; Kekesi et al., 2015; Khan et al., 2016; Deshpande et al., 2017). As expression of CX43, the major connexin isoform expressed by astrocytes, is altered in response to inflammation or demyelination (Brand-Schieber et al., 2005; Markoullis et al., 2014; Masaki, 2015) and inflammatory cytokines increase connexin open probability (Retamal et al., 2007; Froger et al., 2010), CX43 immunostaining was assessed in the HBSFRC cohort. CX43 staining intensity was comparable between MS & MS+S specimens in the CA1 (Figure 6A and D) and DG (Figure 6C and F). In contrast, CX43 intensity was elevated in MS+S CA3 relative to MS only (Figure 6B and E). No difference was observed in immunoreactive area fraction in any region analyzed.
Figure 6.

CX43 expression is enhanced in MS+S CA3 within the HBSFRC cohort. A–C: Representative 20X micrographs showing CX43 (cyan) with nuclear counterstain (DAPI; red) in CA1, CA3, & DG of MS & MS+S hippocampi. Insets a & b show digitally magnified area within dashed boxes for detail. D–F: Normalized CX43 immunoreactive signal intensity in MS & MS+S CA1 (D), CA3 (E), and DG in shown in arbitrary units (A.U.). Relative to MS, CX43+ signal intensity was greater in CA3 of MS+S specimens. No difference was observed in CA3 or DG. Unpaired t test.

CX43 expression is enhanced in MS+S CA3 within the HBSFRC cohort. A–C: Representative 20X micrographs showing CX43 (cyan) with nuclear counterstain (DAPI; red) in CA1, CA3, & DG of MS & MS+S hippocampi. Insets a & b show digitally magnified area within dashed boxes for detail. D–F: Normalized CX43 immunoreactive signal intensity in MS & MS+S CA1 (D), CA3 (E), and DG in shown in arbitrary units (A.U.). Relative to MS, CX43+ signal intensity was greater in CA3 of MS+S specimens. No difference was observed in CA3 or DG. Unpaired t test.

Discussion

In the current study, we sought to shed light on the pathogenesis of seizures in MS by examining hippocampi of MS and MS+S donors obtained from the UCLA HBSFRC. Specifically, we assessed changes to astrocytes that could lead to dysregulated neuronal excitation, including expression of molecules associated with synaptic glutamate clearance and spatial K+ buffering as well as response to inflammation or injury. We found that, although demyelinated lesion burden was comparable among the tissues acquired from the HBSFRC, astrocyte dysfunction in MS+S specimens relative to MS varied by hippocampal subregion (Table 3). Based on these findings, we constructed a model summarizing how our observations could contribute to neuronal hyperexcitability in MS (Figure 7).
Table 3.

Comparison of Biomarker Expression in MS+S Hippocampal Subregions Versus MS Only.

Changes in- CA1CA3DG
Astrogliosis
Water homeostasis
Synaptic glutamate clearance
Connexin expression
Figure 7.

Model summarizing MS+S neuropathology differing from MS only and its Impact on neuronal excitability. A: Reduced EAAT2 expression suggests aberrant elevation of synaptic glutamate concentration in MS+S, resulting in protracted, higher amplitude post-synaptic response. B: Decreased AQP4 expression and localization away from blood vessels in MS+S suggests compromised K+ removal, thereby raising resting membrane potential (RMP) and reducing synaptic input required to initiate action potential. C: Increased synaptic glutamate and more depolarized RMP increase the frequency of synaptic potentials experienced by principle neurons, leading to generation of high amplitude excitatory discharge and seizure. D: Increased CX43 expression in CA3 may represent enhanced gap junction coupling among astrocytes or proliferation of uncoupled hemichannels, rendering its relevance unclear in the context of MS+S.

Comparison of Biomarker Expression in MS+S Hippocampal Subregions Versus MS Only. Model summarizing MS+S neuropathology differing from MS only and its Impact on neuronal excitability. A: Reduced EAAT2 expression suggests aberrant elevation of synaptic glutamate concentration in MS+S, resulting in protracted, higher amplitude post-synaptic response. B: Decreased AQP4 expression and localization away from blood vessels in MS+S suggests compromised K+ removal, thereby raising resting membrane potential (RMP) and reducing synaptic input required to initiate action potential. C: Increased synaptic glutamate and more depolarized RMP increase the frequency of synaptic potentials experienced by principle neurons, leading to generation of high amplitude excitatory discharge and seizure. D: Increased CX43 expression in CA3 may represent enhanced gap junction coupling among astrocytes or proliferation of uncoupled hemichannels, rendering its relevance unclear in the context of MS+S. Surprisingly, the MS+S CA1 displayed the greatest number of changes compared to the MS group. In addition to GFAP+ astrogliosis surpassing that seen in MS, AQP4 and EAAT2 were less robustly expressed in the MS+S CA1. These phenomena could promote seizures; EAAT2’s activity accounts for roughly 95% of synaptic glutamate buffering in the adult mammalian CNS (Bergles & Jahr, 1998). Underscoring the critical role it plays in regulating neuronal excitability, hypofunction mutations to SLC1A2 are sufficient to generate severe pediatric epilepsy (Guella et al., 2017), with seizure severity depending on the site of lost EAAT2 performance(Sugimoto et al., 2018). Although both neurons and glia express EAAT2 (Danbolt et al., 2016), genetic ablation from neurons results in no gross phenotype, while its loss from astrocytes produces severe behavioral abnormalities and lethal seizures (Petr et al., 2015). Thus, the reduced EAAT2 signal observed in the MS+S CA1 in the present study may increase seizure susceptibility by abnormally bolstering synaptic glutamate concentrations (Figure 7A). The second way that these data could contribute to seizure vulnerability in MS patients is inferred from the suppression of AQP4 expression seen in the MS+S CA1 & CA3. AQP4 is a passive water channel expressed primarily by astrocytes that is enriched in endfeet contacting blood vessels, which contributes to normal extracellular space volume, glymphatic solute clearance, and K+ buffering (Mestre et al., 2018). Loss of perivascular AQP4 results in delayed K+ clearance and protracted stimulation-evoked seizures, potentially leading to hyperexcitability pursuant to loss of K+ charge separation (Strohschein et al., 2011; Figure 7B). Indeed, AQP4 expression is perturbed throughout epileptic hippocampi, with loss of its normal perivascular distribution in the CA1 (Eid et al., 2005). These observations have parallels in results obtained from the HBSFRC cohort: in addition to the decreased expression noted, perivascular AQP4 expression was sparse in the MS+S CA1, hinting at a role for this molecular in seizure etiology in MS. Of note, seizures are less common in patients with neuromyelitis optica spectrum disorder (NMOSD), a demyelinating disease related to MS characterized by circulating anti-AQP4 IgG, than MS patients(Hamid et al., 2018). As internalization of perivascular AQP4 is also observed at astrocyte endfeet in NMOSD, the contribution of reduced AQP4 to the genesis of seizures in MS requires additional study (Hinson et al., 2017). While postmortem studies resist conclusions regarding function, these data suggest MS+S may involve two hits; persistently elevated extracellular K+ concentration engendered by reduced perivascular AQP4 could lower seizure threshold by mildly depolarizing neurons. Simultaneously, reduced EAAT2 could suppress efficiency of neurotransmission-released glutamate clearance, leading to stronger and more frequent ionotropic glutamate receptor mediated synaptic potentials. Thus, with more glutamatergic neurotransmission and less input needed to elicit an action potential in affected neurons, these data may represent one way that the MS+S CA1 is predisposed to seizure (Figure 7C). Considering that loss of inhibitory neuron populations is also observed in various brain regions during demyelinating disease, GABAergic containment of pathological excitation may be insufficient to stem its spread to neighboring structures (Ziehn et al., 2010). While these data point to one plausible means of propagating seizures in MS, the finding that CX43 expression is enhanced in the MS+S CA3 raises several questions regarding the nature of such upregulation. In the brain, glia are the foremost expressers of connexin proteins, which link astrocytes and oligodendrocytes into a glial syncytium. This network of interconnected cells facilitates spatial K+ buffering and propagation of Ca2+ waves through gap junction (GJ)-mediated direct cytoplasmic coupling (Lapato & Tiwari-Woodruff, 2018). Additionally, uncoupled connexin hemichannels facing the extracellular space are thought to modulate neurotransmission via release of so-called gliotransmitters, such as purines, D-serine, and glutamate(Durkee & Araque, 2019). In the present study, CX43 expression was increased in MS+S CA3, which has parallels in epileptic brain tissue (Wu et al., 2015), however, whether this represents increased GJ-coupling or hemichannel mobilization cannot be inferred from this study (Figure 7D). Notably, the finding that demyelinated lesion burden was comparable between HBSFRC cohorts departs from data published by Calabrese et al. (Calabrese et al., 2017). This is perhaps unsurprising given the small cohort sizes available for each study (23 RRMS patients with seizures were enrolled in (Calabrese et al., 2017) and 7 specimens here). Methodological differences may also contribute to the discrepancy between the two studies. GMLs were identified in (Calabrese et al., 2017) solely by 3 Tesla MRI using a double inversion recovery protocol, whereas here, chromogen immunoreaction and transmitted light microscopy were used. Given the studies’ cohort sizes, methodological differences, and the variable extent to which MRI and histology probe the same phenomena, it is difficult to assess whether these studies are in opposition (Xiao et al., 2010; Noristani et al., 2015; Atkinson et al., 2019). Additional investigation is warranted to examine many aspects of seizures in MS and may benefit from comprehensive analysis of the correlation between double inversion recovery MRI and histopathology. Despite this uncertainty, several scenarios are plausible given our understanding of how inflammatory demyelination affects connexin dynamics. Both oligodendrocyte death and inflammatory cytokines diminish GJ coupling and increase hemichannel open probability (Lapato & Tiwari-Woodruff, 2018). If the increased CX43 observed represents more abundant hemichannels, the proinflammatory cytokine milieu encountered by astrocytes could augment release of glutamatergic and purinergic signaling molecules through hemichannels permeable to to the extracellular space (Chever et al., 2014a). In such a case, hemichannel blockade could ameliorate seizures in MS+S, as similar interventions have proven to reduce seizure severity in animal models of epilepsy associated with greater hemichannel activity (Walrave et al., 2018). An alternative interpretation of increased CX43 pertains to increased GJ coupling in the MS+S CA3. CX43+ GJs couple astrocytes to one another and to oligodendrocytes, thereby facilitating movement of K+ from areas of depolarizing activity to blood vessels for removal (Fasciani et al., 2018). This may, therefore, represent a compensatory mechanism in the seizure prone MS+S hippocampus to address chronically elevated extracellular K+ concentrations. Lending credence to this possibility, decreased AQP4 expression positively regulates CX43 (Katoozi et al., 2017). While the physiological relevance of such compensation is unclear, reports link connexin-mediated astrocyte synchrony to neuronal burst firing during seizures in acute hippocampal slices (Kekesi et al., 2015). To resolve this question, a greater degree of experimental manipulation is necessary. The cuprizone (CPZ) model may be useful for studying MS+S. Mice given 0.2% dietary CPZ display behavioral and electrographic seizures (Lapato et al., 2017) that are associated with loss of CA1 inhibitory neurons, specifically parvalbumin+ cells, mirroring cortical MS+S neuropathology (Nicholas et al., 2016). Astrocytes from these mice also exhibit loss of domain organization, membrane varicosities suggestive of energetic failure, and perturbed AQP4 & EAAT2 expression (Lapato et al., 2017). The parallel between these observations and MS+S astrocytes suggests the CPZ model may be translationally useful and future studies should validate this comparison. Overall, even though MS+S patients represent a minority of the population with MS, the greater morbidity & mortality as well as decreased quality of life in this group behooves further investigation of the pathology, cellular and molecular mechanisms leading to seizures in these patients. Click here for additional data file. Supplemental material, sj-pdf-1-asn-10.1177_1759091420979604 for Astrocyte Glutamate Uptake and Water Homeostasis Are Dysregulated in the Hippocampus of Multiple Sclerosis Patients With Seizures by Andrew S. Lapato, Sarah M. Thompson, Karen Parra and Seema K. Tiwari-Woodruff in ASN Neuro
  90 in total

1.  Epilepsy in multiple sclerosis.

Authors:  A Ghezzi; R Montanini; P F Basso; M Zaffaroni; E Massimo; C L Cazzullo
Journal:  Eur Neurol       Date:  1990       Impact factor: 1.710

2.  Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage.

Authors:  P Werner; D Pitt; C S Raine
Journal:  Ann Neurol       Date:  2001-08       Impact factor: 10.422

3.  Aphasic status epilepticus in multiple sclerosis.

Authors:  A Primavera; M V Gianelli; F Bandini
Journal:  Eur Neurol       Date:  1996       Impact factor: 1.710

4.  Epilepsy in patients with multiple sclerosis: radiological-clinical correlations.

Authors:  T Moreau; D Sochurkova; M Lemesle; G Madinier; T Billiar; M Giroud; R Dumas
Journal:  Epilepsia       Date:  1998-08       Impact factor: 5.864

Review 5.  Altered Kir and gap junction channels in temporal lobe epilepsy.

Authors:  Peter Bedner; Christian Steinhäuser
Journal:  Neurochem Int       Date:  2013-01-26       Impact factor: 3.921

6.  Multiple sclerosis and seizures: incidence and prevalence over 40 years.

Authors:  C Lund; K O Nakken; A Edland; E G Celius
Journal:  Acta Neurol Scand       Date:  2014-09-10       Impact factor: 3.209

7.  Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination.

Authors:  Daniel K Crawford; Mario Mangiardi; Bingbing Song; Rhusheet Patel; Sienmi Du; Michael V Sofroniew; Rhonda R Voskuhl; Seema K Tiwari-Woodruff
Journal:  Brain       Date:  2010-09-21       Impact factor: 13.501

8.  Increase in chemokine CXCL1 by ERβ ligand treatment is a key mediator in promoting axon myelination.

Authors:  Hawra Karim; Sung Hoon Kim; Andrew S Lapato; Norio Yasui; John A Katzenellenbogen; Seema K Tiwari-Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

9.  Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment.

Authors:  Seema Tiwari-Woodruff; Laurie Beth J Morales; Ruri Lee; Rhonda R Voskuhl
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-04       Impact factor: 11.205

10.  Seizure characteristics in multiple sclerosis patients.

Authors:  Vahid Shaygannejad; Fereshteh Ashtari; Mohammad Zare; Majid Ghasemi; Rasul Norouzi; Helia Maghzi
Journal:  J Res Med Sci       Date:  2013-03       Impact factor: 1.852

View more
  1 in total

Review 1.  Neuroinflammation: A Signature or a Cause of Epilepsy?

Authors:  Enrico Pracucci; Vinoshene Pillai; Didi Lamers; Riccardo Parra; Silvia Landi
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.